Eyegate Pharmaceuticals (NASDAQ: EYEG) is one of 104 public companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare Eyegate Pharmaceuticals to related businesses based on the strength of its analyst recommendations, profitability, earnings, risk, dividends, valuation and institutional ownership.

Institutional & Insider Ownership

13.1% of Eyegate Pharmaceuticals shares are owned by institutional investors. Comparatively, 43.9% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 24.6% of Eyegate Pharmaceuticals shares are owned by insiders. Comparatively, 11.3% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Eyegate Pharmaceuticals and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eyegate Pharmaceuticals 0 0 4 0 3.00
Eyegate Pharmaceuticals Competitors 858 3777 6721 178 2.54

Eyegate Pharmaceuticals currently has a consensus price target of $7.00, suggesting a potential upside of 542.20%. As a group, “Pharmaceuticals” companies have a potential upside of 26.36%. Given Eyegate Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Eyegate Pharmaceuticals is more favorable than its peers.

Profitability

This table compares Eyegate Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Eyegate Pharmaceuticals -1,737.29% -840.69% -105.23%
Eyegate Pharmaceuticals Competitors -2,389.76% -60.07% -7.42%

Volatility and Risk

Eyegate Pharmaceuticals has a beta of 3.26, meaning that its share price is 226% more volatile than the S&P 500. Comparatively, Eyegate Pharmaceuticals’ peers have a beta of 36.54, meaning that their average share price is 3,554% more volatile than the S&P 500.

Earnings & Valuation

This table compares Eyegate Pharmaceuticals and its peers gross revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Eyegate Pharmaceuticals $670,000.00 -$13.34 million -0.84
Eyegate Pharmaceuticals Competitors $8.17 billion $1.09 billion 163.44

Eyegate Pharmaceuticals’ peers have higher revenue and earnings than Eyegate Pharmaceuticals. Eyegate Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Eyegate Pharmaceuticals peers beat Eyegate Pharmaceuticals on 7 of the 12 factors compared.

About Eyegate Pharmaceuticals

Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.

Receive News & Ratings for Eyegate Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.